Interleukin (IL)‐1β, in turn, drove an immune inhibitory phenotype on tumor cells, especially on the increase in programmed death‐ligand 1, by activating the nuclear factor‐κB (NF‐κB) signaling pathway. The gene discussed is NFKB1; the disease is neoplasm.